Strategic Licensing NeoTX's proprietary oncology-immunotherapy pipeline, reinforced by recent acquisitions of InterX and Hookipa assets, positions the company as a compelling target for licensing or co-development deals with larger pharma seeking to bolster their IO portfolios. Opportunities exist for milestone-driven collaborations and asset-specific out-licensing that align with NeoTX's clinical-stage status.

Partnership Model As a lean, early-stage company with substantial funding, NeoTX can attract CROs, CMOs, and manufacturing partners for cost-efficient development, enabling risk sharing and faster progression of assets into clinical trials through strategic partnerships.

Pipeline Acceleration The integration of InterX assets and Hookipa asset sales expands NeoTX's pipeline, offering multiple collaboration tracks with academic centers and biotech partners to validate targets, extend indications, and create co-development opportunities across oncology indications.

Globalization Path NeoTX's Israel base and leadership team experience present a compelling case for US/EU-focused partnerships to navigate regulatory processes, run multi-region trials, and accelerate commercialization, supported by regional CRO networks and potential manufacturing partnerships.

Financial Readiness With revenue in the lower end of the scale and existing funding of around forty-five million dollars, NeoTX may entertain milestone-based financings, strategic investments, or in-licensing deals that offer near-term value realization while sustaining R&D momentum.